Laura Michaelis, MD, discusses the next steps for research in the treatment of myelofibrosis following the addition of fedratinib to the armamentarium of JAK inhibitors.
Laura Michaelis, MD, an associate professor at the Medical College of Wisconsin, discusses the next steps for research in the treatment of myelofibrosis (MF) following the addition of fedratinib (Inrebic) to the armamentarium of JAK inhibitors.
Since ruxolitinib (Jakafi) was brought to market, research has come a long way, Michaelis says. However, some unanswered questions still exist, such as how necessary is it to eradicate the clone? With better stratification systems now and patients with MF living longer than before, additional treatment may not be needed. There is a category of patients that can be observed, she notes.
If a patient presents with higher-risk disease, Michaelis asks how are we modifying the disease? How are we getting to the root of it? JAK inhibitors may not be the answer, although they are good for splenic response and symptom reduction. Whether or not more drugs need to be used earlier, including in patients who have lower risk of disease, and whether additional drugs are needed that tackle the clone at a lot of different areas of vulnerability are 2 remaining questions to be addressed.
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More